Argos Therapeutics Inc. (NASDAQ:ARGS) shot up 4.2% during mid-day trading on Monday . The stock traded as high as $4.97 and last traded at $4.96, with a volume of 146,901 shares traded. The stock had previously closed at $4.76.

Several brokerages have issued reports on ARGS. Roth Capital increased their price target on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 19th. Needham & Company LLC restated a “buy” rating on shares of Argos Therapeutics in a report on Saturday, April 23rd. Zacks Investment Research downgraded Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $11.84.

The firm’s 50-day moving average price is $5.78 and its 200-day moving average price is $5.80. The company’s market capitalization is $123.37 million.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. Analysts predict that Argos Therapeutics Inc. will post ($1.68) EPS for the current year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.